JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Smith & Nephew PLC ADR

Fermé

34.23 0.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

33.95

Max

34.23

Chiffres clés

By Trading Economics

Revenu

296M

Ventes

3B

P/E

Moyenne du Secteur

30.423

90.422

Rendement du dividende

2.26

Marge bénéficiaire

9.895

Employés

17,000

EBITDA

723M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+0.94% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.26%

2.13%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

15B

Ouverture précédente

33.85

Clôture précédente

34.23

Score Technique

By Trading Central

Confiance

Bullish Evidence

Smith & Nephew PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 févr. 2026, 23:52 UTC

Acquisitions, Fusions, Rachats

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 févr. 2026, 23:52 UTC

Acquisitions, Fusions, Rachats

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 févr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 févr. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 févr. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 févr. 2026, 23:23 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 févr. 2026, 22:57 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 févr. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 févr. 2026, 21:51 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 févr. 2026, 21:49 UTC

Résultats

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 févr. 2026, 21:39 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:36 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 févr. 2026, 21:34 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:28 UTC

Acquisitions, Fusions, Rachats

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 févr. 2026, 21:23 UTC

Résultats

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 févr. 2026, 21:19 UTC

Résultats

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 févr. 2026, 21:17 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 févr. 2026, 21:17 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:10 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:08 UTC

Résultats

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 févr. 2026, 21:07 UTC

Résultats

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Net $608.7M >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Rev $1.41B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q EPS 24c >PLTR

2 févr. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparaison

Variation de prix

Smith & Nephew PLC ADR prévision

Objectif de Prix

By TipRanks

0.94% hausse

Prévisions sur 12 Mois

Moyen 34.46 USD  0.94%

Haut 34.91 USD

Bas 34 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

26.64 / 28.37Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat